India's cancer drug price cut explained: what the cap on 137 drugs means for patients

Most health policy stories start in a ministry. This one started with a patient. Sarojam Radhakrishnan, a retired bank employee in Kerala, was diagnosed with breast cancer in 2021 and prescribed targeted drugs costing more than ₹63,000 a month, The Guardian reported. She took the government to court in 2022. She died that September, before her case was decided. Four years later, her petition has changed the price of cancer care in India.

What exactly is changing

The cut is about margins, not the factory price. A 30% cap on trade margins has applied to 42 cancer drugs for some years. Prodded by the Supreme Court's findings, the government has now extended that cap to 137 more, with effect from next month, according to The Guardian. The Department of Pharmaceuticals said it expects prices to fall by up to 70% and patients to save ₹2,500 crore a year.

Why margins? Because that is where the money was. During a hearing on 29 September, Justices Vikram Nath and Sandeep Mehta noted a life saving drug supplied to hospitals at ₹2,700 being sold for ₹27,000. National Pharmaceutical Pricing Authority analysis found trade mark-ups on some cancer drugs averaging 170%, with extreme cases above 700%. The judges called it "extortion".

Why it matters so much

India records about 1.56 million new cancer cases a year, up from 1.39 million in 2020, The Guardian notes. Studies by the Public Health Foundation of India show healthcare spending pushes about 55 million Indians a year below the poverty line. Ayushman Bharat covers some cancers, but its ₹5 lakh annual family cover equals the cost of a single dose of the breast cancer drug Kadcyla, and a patient may need up to 14 doses.

The surgical oncologist Ravi Kannan described families who start treatment but do not come back for chemotherapy because they cannot sustain the cost. Lower drug bills will not solve that alone, but they make finishing treatment more likely.

What it will not fix

Here is the catch. Jyotsna Singh of the Working Group on Access to Medicines and Treatments warned that hospitals may offset lower drug prices by raising charges on other items. That worry is not abstract. The Centre has told the Supreme Court that margins on hospital consumables can range from 100% to over 1,000%, yet a senior official said the government lacks the data to assess them, ET HealthWorld reported. The court has asked why the cap should apply only to cancer drugs and not all non patented drugs, and gave the government until 27 October to respond.

What patients and families can do

Ask for an itemised bill and check drug prices against the printed maximum retail price. Ask whether a capped drug is available at the hospital pharmacy and outside it. Keep every receipt. And watch for the government's reply to the court, since a wider cap would help far more families.

The science worth watching

The research news this week was unusually hopeful. A personalised vaccine from MSD and Moderna, given with immunotherapy, cut the risk of melanoma patients dying or their cancer returning by 42% in a major trial, the BBC reported. Adding Amgen's Imdelltra to AstraZeneca's Imfinzi cut the risk of death by 58% in extensive stage small cell lung cancer, with median survival of 21.1 months against 12.7 months, CNBC reported. A Mayo Clinic led phase 2 trial found an investigational vaccine helped the immune system respond to the KRAS mutations behind most pancreatic cancers, Medical Xpress reported.

A note of caution. An analysis reported by STAT found just 31% of 97 approved cancer drug indications in Europe over four years offered high clinical benefit. New does not always mean better, and new is rarely cheap.

The bigger lesson

Cancer care is not only about drugs. Prevention, early diagnosis and cleaner environments matter too. Anyone who wants to study that link on the ground can look at Earth5R's FIELDWORK fellowship, where fellows do real fieldwork with real communities and get it independently verified. And one bank clerk's petition is a reminder that patients asking hard questions can move a whole system.